Mumbai, India — April 27, 2026
India’s largest drugmaker, Sun Pharmaceutical Industries, has announced a landmark agreement to acquire U.S.-based Organon & Co. in a deal valued at approximately $11.75 billion, marking the company’s biggest overseas acquisition to date.
The transaction involves the purchase of 100% equity shares of Organon at $14 per share. According to company disclosures, the total enterprise value stands at $11.75 billion, while the equity valuation is estimated at around $3.99 billion.
Sun Pharma said the acquisition aligns with its long-term strategy to expand its global footprint, particularly in innovative medicines, branded formulations, and generics. The deal is also expected to significantly strengthen the company’s presence in the biosimilars segment—an increasingly competitive and fast-growing area of the global pharmaceutical market.
Strategic Expansion and Global Positioning
Following the acquisition, the combined entity is projected to rank among the top 25 pharmaceutical companies globally, with an estimated annual revenue of approximately $12.4 billion.
The deal is expected to enhance Sun Pharma’s portfolio in key segments such as women’s health and biosimilars, while also expanding its reach across developed and emerging markets.
Organon, headquartered in New Jersey, operates in more than 140 countries and offers a portfolio of over 70 products focused on women’s health, biosimilars, and established medicines.
Leadership Commentary
Sun Pharma Chairman Dilip Shanghvi said the acquisition would make the company more diversified and globally competitive. Managing Director Kirti Ganorkar added that the deal is expected to unlock significant growth opportunities and operational synergies.
Funding and Deal Timeline
The company plans to finance the acquisition through a combination of internal accruals and debt. The transaction has already received approval from the boards of both companies and is currently awaiting regulatory clearances and shareholder approvals.
The deal is expected to close by early 2027, subject to customary conditions.
Market Reaction
Following the announcement, Sun Pharma’s stock surged sharply. Shares rose by approximately 6.7% during Monday’s trading session, reaching a high of ₹1,728.65, reflecting strong investor confidence in the company’s expansion strategy.
Industry Impact
Analysts view the acquisition as a significant milestone for India’s pharmaceutical sector, signaling a shift toward larger global ambitions. If completed, the deal could reshape competitive dynamics in the global drug industry and elevate Sun Pharma’s position among leading multinational pharmaceutical players.
